Phase 2 findings suggest that fit patients with AML fare better with a gentler regimen than with standard induction ...

The FDA granted final approval to Alembic's generic venetoclax tablets, rated therapeutically equivalent to Venclexta, for CLL/SLL and newly diagnosed AML.

Sellas’ Phase 3 Regal leukemia trial reached its 80th event, triggering final analysis. ・Preliminary topline results are due ...

A large EBMT registry analysis of 3385 adults with AML in remission and measurable residual disease found that haploidentical ...

Hydroxyurea vs. hypomethylating vs. other agents in chronic myelomonocytic leukemia: A retrospective inspection of treatment strategies among 457 Mayo Clinic patients. This is an ASCO Meeting Abstract ...

Reaching the Pre-Specified 80th Event Triggers the Final Analysis of the Pivotal Phase 3 Trial - - Company to Report Topline Primary Endpoint Results this Quarter - NEW YORK, Oct. 28, 2026 (GLOBE ...

The activity of six different genes can help determine survival in patients with acute myeloid leukemia (AML), according to a ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Subscribe to ...

The exact cause of acute myeloid leukemia (AML) is unclear, but risk factors can include older age, radiation exposure, smoking, certain genetic conditions, and more. Acute myeloid leukemia (AML) is a ...

Key TakeawaysSellas shares fell 18% today after the company said its Phase 3 REGAL trial in acute myeloid leukemia reached the 80th death, which triggers the trial’s final analysis. The drop looks ...

An integrative single-cell and bulk transcriptomic analysis identified an eight-gene non-LSC17 companion program associated ...